Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloNK and Rituximab in Relapsing B-cell Dependent Rheumatologic Diseases
NCT06991114Phase 2Recruiting
- Sponsor
- Artiva Biotherapeutics, Inc.
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 11
01
Overview
A Phase 2 trial of Natural killer cell infusion in rheumatoid arthritis (RA), Sjögren's syndrome, idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc), sponsored by Artiva Biotherapeutics, Inc.. Started Jul 2025; status: recruiting.
02
Drugs
Natural killer cell infusion
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndromeidiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06991114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991114.